Table 1 Patient characteristics.
Clinical variables | Number (N) | Percentage (%) |
|---|---|---|
 Total number of patients | 99 |  |
Gender | ||
 Male | 81 | 81.37 |
 Female | 18 | 18.62 |
Age (years) Median (range) | 60 (28–79) |  |
Smoking status (Y/N) | 76/23 | 76.76 |
Tumor size (cm) (study population) | ||
 (population median/range) | 4.3/(1.5–10) |  |
 Large (≥ 4.3 cm) | 51 | 51.51 |
 Small (< 4.3 cm) | 48 | 48.48 |
Tumor size (cm) (AUA guideline) | ||
 Large (≥ 3 cm) | 83 | 83.83 |
 Small (< 3 cm) | 16 | 16.16 |
Lymphovascular Invasion (LVI) | N = 99 |  |
 Yes | 37 | 37.37 |
 No | 62 | 62.62 |
T stage | N = 99 |  |
 T2 | 81 | 81.81 |
 T3/T4 | 18 | 18.18 |
N status (lymph node) | N = 99 |  |
 N0 | 74 | 74.74 |
 N1 or more | 25 | 25.25 |
Hydronephrosis | N = 99 |  |
 Yes | 59 | 59.59 |
 No | 40 | 40.40 |
Early intravesical therapy | N = 7 | 7.07 |
 BCG therapy | 6 | 85.71 |
 Mitomycin | 1 | 14.28 |
NACT received | N = 32 | 32.32 |
 GC (Gemcitabine-cisplatin) | 17 | 53.12 |
 ddMVAC | 15 | 46.87 |
Pathological response (post NACT treatment) | N = 32 | 32.32 |
 Complete | 6 | 18.75 |
 Partial/no-response | 26 | 81.25 |
